Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (107)	1/13/1999 1:11:00 AM
From: Dennis C	Read Replies (1) \| Respond to of 1834

"However, hundreds of thousands compounds per day (how many compounds do NBIX have?, maybe 1-200K) is old phrase which immediately cool me off. Now. all what NBIX need is +4 MM compounds from PCOP libraries, identified lead, optimized and license to large pharma for big bucks." Miljenko: NBIX purchased a lot of compounds from different sources. They also have a good chemistry team. Recently they hired a new VP who had worked for CombiChem. Hope this is a great match for the deal released today. Do you have idea about the average cost/compound/screening? If the number is $ 0.5/cpds, it would cost 0.5$ x 200K(your number)x 35 (assay)= 3,5 million. If they screen 4 MM, the number would be $70 million. dc